期刊文献+

脓毒性心肌功能障碍 被引量:7

Septic Myocardial Dysfunction
原文传递
导出
摘要 脓毒症是由感染引起的全身炎症反应综合征,证实有感染灶存在或有高度可疑的感染灶。脓毒症是ICU内重症患者的主要死亡原因,且发病率随着年龄的增长而逐渐增加。近十年来,虽然政府在救治脓毒症患者中投入了巨大的资金和技术支持,但源于脓毒症或脓毒性休克患者的病死率仍高达30%-60%。心血管系统在脓毒症与脓毒性休克的病理生理学中扮演着重要着色。过去的四五十年,开展了很多脓毒性心肌功能障碍方面的研究,也积累了不少循证医学证据。然而,心脏只是心血管系统的一部分。诸如脓毒症患者机体血流动力学的变化系脓毒症对心脏的直接效应,还是脓毒症引起心脏前、后负荷及神经体液因素的变化,继而引起心脏继发改变的研究,至今仍在继续。本文概述了近年来脓毒性心肌功能障碍的研究进展,使读者更全面地了解脓毒性心肌功能障碍的病理生理学改变,合理有效地指导脓毒症和脓毒性休克患者的临床救治。 Sepsis is systemic inflammatory response syndrome caused by the focus of infection or potentially suspicious focus of infection. Sepsis is a major cause of critical patients in the intensive care unit (ICU), and its incidence is constantly increasing with the aging and growth of the population. Mortality rate from severe sepsis or septic shock still ranges from 30% to 60% over the last decades despite the aggressive treatment and the enormous costs invested by official government. The cardiovascular system plays a key role in the pathophysiology of sepsis and septic shock. The evidence for myocardial dysfunction in septic shock has been accumulated in numerous studies over the last 40 to 50 years. Nevertheless, because the heart is only one part of the cardiovascular system, the studies on the correlations between the change of hemodynamics and the direct effects of sepsis on the heart, or the changes in preload, afterload and neurohumoral activity are continuing up to now. The purpose of this article is to review the studies on septic myocardial dysfunction, and make readers better understand the viewpoints of its mechanism nowadays, and put these theories into clinical treatment on the patients with sepsis or septic shock effectively.
出处 《现代生物医学进展》 CAS 2015年第3期538-542,共5页 Progress in Modern Biomedicine
基金 国家重大基础理论研究发展(973)计划项目(2012CB518905) 唐都医院科技创新发展基金重大临床研究项目(2013-4241370U2)
关键词 心肌功能障碍 脓毒症 严重脓毒症 脓毒性休克 Myocardial Dysfunction Sepsis Severe sepsis Septic Shock
  • 相关文献

参考文献41

  • 1Krausz MM, Perel A, Eimerl D, et al. Cardiopulmonary effects of volume loading in patients in septic shock [J]. Ann Surg, 1977, 185: 429-434.
  • 2Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin [J]. N Engl JMed, 1989, 321:280-287.
  • 3Kumar A, Anel R, Bunnell E, et al. Preload-independent mechanisms contribute to increased stroke volume following large volume saline infusion in normal volunteers: A prospective interventional study[J]. Crit Care, 2004, 8:128-136.
  • 4Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock [J]. N Engl J Med, 2001, 345:1368-1377.
  • 5Brandt S, Regueira T, Bracht H, et al. Effect of fluid resuscitation on mortality and organ function in experimental sepsis models [J]. Crit Care, 2009, 13:186.
  • 6Taveira D, Silva AM, Kaulbach HC, et al. Brief report: Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin[J]. N Engl J Med, 1993, 328:1457-1460.
  • 7De Backer D, Creteur J, Preiser JC, et al. Microvascular blood flow is altered in patients with sepsis [J]. Am J Respir Crit Care Med, 2002, 166:98-104.
  • 8S uffredini AF, Shelhamer JH, Neumann RD, et al. Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans[J]. Am Rev Resp Dis, 1992, 145:1398-1403.
  • 9van Eijk LTGJ, Pickkers P, Smits P, et al. Microvascular permeability during experimental human endotoxemia: An open intervention study [J]. Crit Care, 2005, 9:157-164.
  • 10Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock[J]. Ann Intern Med, 1984, 100:483-490.

同被引文献88

  • 1I)ellinger RP,Levy MM,Rhodes A,et al. Sutwiving sepsis cam- paign:international guidelines fr management of severe sepsis and septic shock,2012[J]. Intensive Care Med,2013,39(2): 165 -228.
  • 2Alejandria MM,Lansang MA,Dans LF,et al. Intravenous imm- unoglobulin for treating sepsis,severe sepsis and septic shock[J]. Cochrane Database Syst Rev,2013,9(16) :CD001090.
  • 3Karnad DR,Bhadade R,Verma PK.et al. Intravenous adminis- tration of ulinastatin(human urinary trypsin inhibitor) in severe sepsis:a inulticenter randomized controlled study[J]. Intensive Cater Med,2014,40(6) : 830-838.
  • 4Wu J,Zhou L,Liu J,et al. The efficacy of thymosin alpha I for severe sepsis(ETASS):a muhicenter,single-blind,randomized and controlled trial [ J ]. Crit Care,2013,17 ( 1 ) : R8.
  • 5Shao C,Tian G,Huang Y,et al. Thymnsin alpha-l-transformed Bifidobacterium premotes T cell proliferation and maturation in mice by oral administration[J]. Int lmmunopharmacol,2013,15 (3) :646-653.
  • 6Pierluigi B,D'Angelo C,Fallarino F,et al. Thymosin alphal: the regulator of regulators[J]. Ann N Y Acad Sci,2010(1194) : 1-5.
  • 7Padfield GJ,Din JN,Koushiappi E,et al. Cardiovascular effects of tumour necrosis factor c antagonism in patients with acute myocardial infarction: a first in human study[J]. Heart,2013, 99(18) : 1330-1335.
  • 8Saraste A,Pulkki K,Kallajoki M,et al. Apoptosis in human acute myocardial infarction [J]. Circulation, 1997,95 (2) :320- 323.
  • 9Grandel U,Fink L,Blum A,et al. Endotoxin-indueed myocar- dial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production[J]. Circula- tion, 2000, 102 (22) : 2758-64.
  • 10Asgeri M,Pourafkari L,Kundra A,et al. Dual effects of tumor necrosis factor alpha on myocardial injury following prolonged hypoperfusion of the heart [J]. Inmmnol Invest,2015,44 (1) : 23-35.

引证文献7

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部